Feds Investigating Prescription Drug Price Increases
Nelson has been critical of the $80 billion agreement. In fact, he called for a larger share of savings from the pharmaceutical manufacturers during a Senate Finance Committee hearing in September.
In an amendment, he proposed that the pharmaceutical industry "surrender a financial windfall" it gets on drugs sold to Medicare patients who also qualify for Medicaid, called "dual eligibles." The amendment, which Nelson said would saved taxpayers an estimated $106 billion over 10 years, was based on estimates provided by the Congressional Budget Office. It was defeated in a 13-10 vote at that time.
Janice Simmons is a senior editor and Washington, DC, correspondent for HealthLeaders Media Online. She can be reached at firstname.lastname@example.org.
- How Top-Ranked MA Plans Earn Their Stars
- WellPoint Dominates Nearly Half of Markets, AMA Says
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- How Hospitals Can Become 'Upstreamists'
- Providers Ask HHS to Address EHR Interoperability Barriers
- 16 Medicare Advantage Plans Earn 5-Star Ratings
- The Drug Price Reform Debate
- Ebola: A Call for Designated Hospitals
- CMS' new investment model will help ACOs with health IT